Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment

Published:2022-10 Issue:10 Volume:111 Page:2652-2661
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Sahin Gokben^ORCID,Akbal-Dagistan Ozlem^ORCID,Culha Meltem^ORCID,Erturk Aybige^ORCID,Basarir Nur Sena^ORCID,Sancar Serap,Yildiz-Pekoz Ayca^ORCID

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference165 articles.

1. SARS and MERS: recent insights into emerging coronaviruses;De Wit;Nat Rev Microbiol,2016

2. WHO Timeline - COVID-19. January 4, 2022. Published 2020. Accessed https://www.who.int/news-room/detail/27-04-2020-who-timeline—covid-19

3. Coronavirus disease (COVID-19) pandemic;WHO,2022

4. Back to the future: inhaled drug products;Hickey;J Pharm Sci,2013

5. Inhalation delivery for the treatment and prevention of COVID-19 infection;Eedara;Pharmaceutics,2021

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel inhalable nano-based/microparticles for enhanced sustained pulmonary delivery of remdesivir - a patient malleable treatment for coronaviruses infection: in vitro aerosolization, cytotoxicity assays and antiviral activity studies.;Journal of Drug Delivery Science and Technology;2024-09

2. Nebulized enriched heparin improves respiratory parameters in patients with COVID-19: a phase I/II randomized and triple-blind clinical trial;Scientific Reports;2024-08-27

3. Dopamine and its precursor levodopa inactivate SARS-CoV-2 main protease by forming a quinoprotein;Free Radical Biology and Medicine;2024-08

4. Inhalable nanomedicine for lung cancer treatment;Smart Materials in Medicine;2024-06

5. Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19;Journal of Antimicrobial Chemotherapy;2024-05-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3